Ertugliflozin + metformin

Trade Name:

Segluromet

Manufacturer/Distributor:

Merck Canada

Classification:

Oral blood glucose lowering agents

ATC Class:

A10BD23 - metformin and ertugliflozin

Status:

active

Notice of Compliance (yyyy/mm/dd):

2018/05/30

Date Marketed in Canada (yyyy/mm/dd):

2018/05/30

Presentation:

Tablet: 2.5 mg ertugliflozin + 500 mg metformin. DIN: 0247615

Tablet: 2.5 mg ertugliflozin + 1000 mg metformin. DIN: 02476223

Tablet: 7.5 mg ertugliflozin + 500 mg metformin. DIN: 02476231

Tablet: 7.5 mg ertugliflozin + 1000 mg metformin. DIN: 02476258

Comments:

This combination product is used as an adjunct to diet and exercise in adult patients with type 2 diabetes who are inadequately controlled on metformin or already controlled with metformin and ertugliflozin as individual components. It is also indicated for use in combination with sitagliptin as an adjunct to diet and exercise in adult patients with type 2 diabetes mellitus who are inadequately controlled on metformin and sitagliptin, or already controlled with metformin, sitagliptin and ertugliflozin, as individual components components.

Keywords:

metformin

Keywords:

ertugliflozin

Keywords:

diabetes mellitus: type 2

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Polyethylene glycol 3350	Pegalax	Laxative
Pomalidomide	Pomalyst	Antineoplastic agent; immunmodulator	2014/02/24
Ponesimod	Ponvory	Sphingosine 1-phosphate receptor modulator	2021/04/28
Prasugrel	Effient	Platelet aggregation inhibitor	2010/05/17
Prasugrel	Effient	Antiplatelet agent	2020/01/31
Pregabalin	Lyrica	Analgesic
Probenecid	Benuryl	Uricosuric agent
Progesterone	Endometrin	Progestin	2010/02/21
Propiverine	Mictoryl; Mictoryl Pediatric	Anticholinergic and antispasmodic agent	2017/04/13
Propofol	Propofol Injection	Anesthetic, sedative	2010/06/01
Propoxyphene	Darvon-N; 642	Narcotic
Prucalopride	Resotran	Enterokinetic agent	2012/01/13
Regorafenib	Stivarga	Antineoplastic agent	2013/03/11
Ribociclib	Kisqali	Antineoplastic agent	2018/11/26
Rilpivirine	Edurant	Antiviral agent	2011/08/08
Risankizumab	Skyrizi	Interleukin-23 inihbitor	2019/05/13
Risedronate	Actonel DR	Bone metabolism regulator	2011/09/28
Risedronate + Calcium carbonate	Actonel APC
Risedronate sodium	Actonel	Bisphosphonate
Roflumilast	Daxas	Phosphodiesterase 4 (PDE4) Inhibitor	2010/11/25
Romosozumab	Evenity	Bone formation agent	2019/08/12
Rosiglitazone + glimepiride	Avandaryl		2011/03/31
Rotigotine	Neupro	Antiparkinsonian agent / Dopamine agonist	2013/09/12
Rufinamide	Banzel	Antiepileptic	2011/09
Rupatadine	Rupall	Antihistamine, second generation	2017/01/25
Ruxolitinib	Jakavi	Antineoplastic agent	2012/07/18
Sacubitril + valsartan	Entresto	Endopeptidase inhibitor, angiotension II receptor antagonist	2015/11/13
Safinamide	Onstryv	Monoamine oxidase B inhibitor	2019/07/10
Salicylic acid + Triclosan	Panoxyl Clear Acne Cleansing Gel
Sapropterin hydrochloride	Kuvan	Used in phenylketonuria	2010/07/05
Sarilumab	Kevzara	Disease modifying anti-rheumatic drug	2017/08/16
Satralizumab	Enspryng	Immunosuppresant	2020/08/26
Saxagliptin	Onglyza	Dipeptidyl peptidase-4 inhibitor; Incretin enhancer	2009/09/14
Saxagliptin + dapagliflozin	Qtern	Oral antihyperglycemic agent	2018/03/20
Saxagliptin + metformin	Komboglyze	Oral antihyperglycemic agent	2013/04/25
Selexipag	Uptravi	Prostacyclin receptor antagonist	2016/04/21